Qualigen Therapeutics Inc.
QLGN | NASDAQ
$3.21
+$0.17 (+5.59%)
At close: Nov 18, 2025, 04:00 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.36 | -0.24 | -11.18 | -11.76 | -87.70 | -188.60 |
PEG Ratio | 0.01 | 0 | 0.20 | 1.16 | 3.72 | -1.05 |
PS Ratio | n/a | n/a | 26.79 | 49.64 | 277.59 | 894.45 |
PB Ratio | 0.25 | 0.57 | -66.30 | 34.19 | 94.74 | 210.54 |
P/FCF Ratio | -1 | -0.24 | -13.53 | -18.23 | -105.53 | -386.52 |
P/OCF Ratio | -1 | -0.24 | -13.53 | -18.67 | -106.54 | -394.84 |
OCF/S Ratio | n/a | n/a | -197.98 | -265.83 | -260.55 | -226.53 |
Debt / Equity Ratio | 0.01 | n/a | -0.62 | 0.24 | 0.10 | 0.03 |
Quick Ratio | 9.30 | 2.33 | 0.28 | 1.07 | 4.26 | 2.61 |
Current Ratio | 9.30 | 2.33 | 0.28 | 1.26 | 4.49 | 2.71 |
Asset Turnover | n/a | n/a | 2.56 | 0.26 | 0.25 | 0.15 |
Interest Coverage | -13.36 | -6.34 | -7.41 | -521.63 | n/a | n/a |
Return on Equity | -69.87% | -229.90% | 637.83% | -290.71% | -108.04% | -111.61% |
Return on Assets | -62.43% | -131.42% | -659.89% | -110.22% | -78.37% | -70.10% |
Return on Invested Capital | -46.99% | -215.07% | 1.4K% | -162.11% | -123.61% | -66.44% |
Dividend Yield | 36.96% | 5.75% | n/a | n/a | n/a | n/a |
Payout Ratio | -13.12% | -1.42% | n/a | n/a | n/a | n/a |
FCF Payout Ratio | -36.87% | -1.36% | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | -0.09% | 13.66% | 23.37% | -66.87% |
Net Profit Margin | n/a | n/a | -257.79% | -422.08% | -316.55% | -474.16% |
Pretax Profit Margin | n/a | n/a | -239.78% | -427.40% | -316.46% | -474.18% |
Operating Profit Margin | n/a | n/a | -217.20% | -360.03% | -400.85% | -294.44% |
FCF Margin | n/a | n/a | -197.98% | -272.23% | -263.05% | -231.41% |
EBITDA Margin | n/a | n/a | -217.12% | -277.74% | -395.15% | -259.27% |
Add to Watchlist
Select watchlists to add or remove QLGN